Dermatitis atópica, Dra Liliana Guevara. 13 de septiembre 2018
Dermatitis atópica
Dra Liliana Guevara.
2018
ICON: Diagnosis and management of allergic conjunctivitis. Miércoles 25 de marzo
ICON: Diagnosis and management of allergic conjunctivitis. Authors: Bielory L1, Delgado L2, Katelaris CH3, Leonardi A4, Rosario N5, Vichyanoud P6. Author information Abstract Ocular allergy (OA), interchangeably known as allergic conjunctivitis, is a common immunological hypersensitivity disorder affecting up to 40% of the population. Ocular allergy has been increasing in frequency, with symptoms of itching, redness, and swelling that significantly impacts an individual's quality of life (QOL). Ocular allergy is an often underdiagnosed and undertreated health problem, because only 10% of patients with OA symptoms seek medical attention, whereas most patients manage with over-the-counter medications and complementary nonpharmacological remedies. The clinical course, duration, severity, and co-morbidities are varied and depend, in part, on the specific ocular tissues that are affected and on immunologic mechanism(s) involved, both local and systemic. It is frequently associat...
Conclusiones:
ResponderEliminar1. La dermatitis atópica es una enfermedad heterogénea.
2. Los cuidados básicos de la piel es la estrategia terapéutica más importante.
3. El advenimiento de terapias biológicas con blancos terapéuticos dirigidos, podría modificar la historia natural de la enfermedad.
4. Recientes estudios han identificado un aumento en el riesgo de desarrollar malignidades de tipo linfoma, con el uso prolongado de inhibidores de la calcineurina.
Artículo recomendado:
ResponderEliminarAtopic dermatitis
Stephan Weidinger1*, Lisa A. Beck2, Thomas Bieber3,4, Kenji Kabashima5
and Alan D. Irvine6,7,8*
Abstract
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease, with a lifetime prevalence of up to 20% and substantial effects on quality of life. AD is characterized by intense itch, recurrent eczematous lesions and a fluctuating course. AD has a strong heritability component and is closely related to and commonly co-occurs with other atopic diseases (such as
asthma and allergic rhinitis). Several pathophysiological mechanisms contribute to AD aetiology and clinical manifestations. Impairment of epidermal barrier function, for example, owing to deficiency in the structural protein filaggrin, can promote inflammation and T cell infiltration.
The immune response in AD is skewed towards T helper 2 cell-mediated pathways and can in turn favour epidermal barrier disruption. Other contributing factors to AD onset include dysbiosis of the skin microbiota (in particular overgrowth of Staphylococcus aureus), systemic immune
responses (including immunoglobulin E (IgE)-mediated sensitization) and neuroinflammation, which is involved in itch. Current treatments for AD include topical moisturizers and anti-inflammatory agents (such as corticosteroids, calcineurin inhibitors and cAMP-specific
3ʹ,5ʹ-cyclic phosphodiesterase 4 (PDE4) inhibitors), phototherapy and systemic immunosuppressants. Translational research has fostered the development of targeted small molecules and biologic therapies, especially for moderate-to-severe disease.
Texto completo:
https://doi.org/10.1038/s41572-018-0001-z